Go from the headline to the evidence.
Research unlocks the analytical layer on every asset and company page: graded featured trials, the full competitive landscape, complete registries, financial history, filings and the readout calendar. Paid subscriptions are coming soon. Sign up free for lifetime access as part of the Pioneer Cohort (first 100).
✓ Every fact traceable to a source✓ Audited against CT.gov & SEC EDGAR✓ Published grading rubric✓ No sponsored rankings, no price targets
Annual · Best value · Save 35%
Research Annual
Coming soon
Annual subscription · opening soon
- ✓Every featured trial graded: design, endpoint, key result, rationale, source
- ✓Full competitive landscape: evidence signal and reported efficacy per competitor
- ✓Complete ClinicalTrials.gov registry per asset, role-tagged and cross-linked
- ✓Sourced financial history, SEC filings, insider transactions, 13F holders
- ✓Readout calendar with per-readout “what to watch” analysis
- ✓Discontinued programs per indication and mechanism, with the reason
- ✓Grounded live Q&A with protocol citations
Monthly · Flexible
Research Monthly
Coming soon
Monthly subscription · opening soon
- ✓Every featured trial graded: design, endpoint, key result, rationale, source
- ✓Full competitive landscape: evidence signal and reported efficacy per competitor
- ✓Complete ClinicalTrials.gov registry per asset, role-tagged and cross-linked
- ✓Sourced financial history, SEC filings, insider transactions, 13F holders
- ✓Readout calendar with per-readout “what to watch” analysis
- ✓Discontinued programs per indication and mechanism, with the reason
- ✓Grounded live Q&A with protocol citations
Coming Soon · Model Context Protocol (MCP)
API & Teams
Programmatic Access
For AI agents, Cursor, Claude Desktop & research teams
- ✓Model Context Protocol (MCP): Native integration for Claude Desktop & Cursor
- ✓14 Diligence Tools: Programmatic trials, evidence grades, competitors & financials
- ✓JSON-RPC Web Endpoint: Streamable HTTPS endpoint at
/api/mcp - ✓Team Workspaces: Shared watchlists, alerts, and multi-seat billing
- ✓Relational CSV & Batch Exports: Uncapped tabular dataset exports for quantitative modeling
Early access invites rolling out to waitlist members
What each tier shows
| Surface | Free | Research | API & Teams |
|---|---|---|---|
| Evidence outlook (the verdict) | Full: state, tier, rationale | Full: state, tier, rationale | Full + programmatic export |
| Featured trials | Which indications, how many | Every trial: design grade, endpoint, key result, rationale, source | Full analytical data + JSON-RPC |
| Competitive landscape | Names, stages, mechanisms | Evidence signal and reported efficacy per competitor, sortable, compare all | Full matrix + API query access |
| Registered studies (CT.gov) | Counts by indication and phase | Every study: title, status, dates, role, featured cross-links | Complete registry via tool calls |
| News record | Three newest announcements | Full history and cross-company mentions | Full history + automated feed ingestion |
| What to watch (readout analysis) | Layout only, values withheld | Per-readout analysis on the asset and calendar pages | Full calendar + event payloads |
| Discontinued programs | Count | Every dead program: who ran it, how far, why it stopped, source | Full graveyard reason & evidence tools |
| Mechanism explanations | Standard explanation | Depth toggle: class, pathway, selectivity notes | Full biology + structured schema |
| Company financial history | Layout only, values withheld | Sourced quarterly revenue, R&D, cash, net burn, per filing | Quarterly SEC metrics via API |
| SEC filings and insider transactions | Layout only, values withheld | Material 8-K/6-K disclosures; Form 4 insider trades, sortable | Full filings + insider tools |
| Institutional holders | Layout only, values withheld | 13F holders with shares and value | 13F ownership via tool calls |
| Company readout calendar | Per-asset dates on each asset page | Company-wide calendar with earnings dates and readout analysis | Full programmatic calendar |
| Company comparison metrics | Roster | Market cap, cash, runway, annualised R&D, metric-specific sorting | Full comparison tool |
| Exports | None | Due Diligence Memo (PDF) & Matrix (PDF) | Relational CSV, batch export & MCP |
| Model Context Protocol (MCP) | None | Web Q&A only | Direct MCP server (/api/mcp) for Claude Desktop & Cursor |
| Team workspaces & multi-seat | 1 user | 1 user | Multi-seat team billing & shared watchlists |
See it on a real page
The competitive landscape for upadacitinib, as the free tier sees it. Research fills the two blurred columns for every competitor, on every asset.
257 competitors in this universe: 12 direct rivals (same mechanism and indication), 2 same-class, 243 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Upadacitinib (Rinvoq): this drug | Approved | Small molecule | JAK, JAK1 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | ||
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | ||
| LNK01001 | Phase 3 | Small molecule | JAK1 | ||
| LW402 | Phase 3 | Small molecule | JAK1 | ||
| QLM3003 | Phase 3 | Small molecule | JAK | ||
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | ||
| GSK2586184 | Phase 2 | Small molecule | JAK1, JAK1 | ||
| IN-115314 | Phase 2 | Small molecule | JAK1 | ||
| JYP0061 | Phase 2 | Small molecule | JAK1 | ||
| ZL-82 | Phase 2 | Small molecule | JAK | ||
| AZD4604 | Phase 2 | — | JAK1 | ||
| AZD0449 | Phase 1 | — | JAK1 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells |
…and 242 more. Research shows the complete landscape.
Want the full version of this page right now? Every signed-in account can unlock up to three full asset or company pages a day, free: open upadacitinib and use today's unlock.